Explore the Agenda
7:30 am Check In, Coffee & Light Breakfast
8:50 am Chair’s Opening Remarks
Extending Biologic Durability To Reduce Treatment Burden & Improve Patient Outcomes
9:00 am From Molecular Design to Clinical Durability: Extending Ocular Half- Life with the Antibody Biopolymer Conjugate (ABC) Platform
- Explore how the ABC Platform increases molecular size and extends ocular residence time
- Review clinical evidence linking tarcocimab’s approximately 20-day ocular halflife to durable disease control and longer dosing intervals
- Discover how the Antibody Biopolymer Conjugate Drug (ABCD) Platform extends ABC into a modular system for the tailored delivery of diverse drug cargos and durable multi-mechanism therapies
9:30 am Session Reserved
10:00 am Ripple’s Epidel Sustained Drug Platform: From Discovery to the Clinic
- Discovery of the Epidel prodrug technology, and the systematic evaluation process that identified ophthalmology
- Building an ophthalmology-focused team from the ground up
- Generating preclinical and clinical proof-of-concept data sets robust enough to secure capital and anchor strategic partnerships
- Advancing proprietary pipeline programs in parallel with partnered development programs, sustaining internal innovation alongside strategic collaboration
10:30 am Speed Networking
A dedicated networking opportunity designed to connect the ophthalmic drug delivery community. Exchange insights with experts across drug development, delivery, formulation, devices, and translational sciences, and discuss the scientific, clinical, and commercial challenges driving innovation in ocular therapeutics.
11:00 am Morning Break & Refreshments
Extending Therapeutic Effect with Long-Acting Retinal Therapies & Enhanced Delivery Systems
11:30 am Harnessing OcuLief Technology to Improve Retinal Drug Durability, Reduce Treatment Burden & Enhance Patient Outcomes
- Explore how Re-Vana’s OcuLief technology enables a high-payload liquid formulation to be delivered through a conventional intravitreal injection and rapidly transformed into a solid implant using visible light, providing sustained drug release directly within the eye
- Understand how OcuLief is designed to overcome the limitations of frequent intravitreal injections by extending therapeutic durability, maintaining local drug exposure, and supporting improved patient adherence in retinal disease management
- Assess the clinical, manufacturing, and regulatory considerations associated with translating light-activated sustained-release implants into practice and discover what is required to achieve broad clinical adoption and commercial success in ophthalmology
12:00 pm Session Reserved
12:30 pm Panel Discussion: Improving Long-Acting Therapy Success Rates Through Real-World Lessons in Durability, Translation & Development
- Join experienced developers and researchers of long-acting ocular therapies to explore lessons from ongoing development to avoid common pitfalls and accelerate development
- Understand why promising durability data often fails to translate from preclinical studies into clinical success and learn how to generate more predictive evidence earlier in development
- Learn how to overcome formulation, delivery, inflammation, and safety challenges while improving durability, efficacy, and patient experience
- Discuss practical strategies for managing development risk, investment timelines, and key decision points to improve long-term clinical and commercial success
1:15 pm Lunch & Networking Break
Enabling Successful Ocular Therapy Delivery Through Device Advancements & Drug Product Integration
2:15 pm Advancing Suprachoroidal Delivery Through Real-World Lessons, Emerging Technologies & Clinical Experience
- Learn from the evolution of suprachoroidal delivery and understand the key breakthroughs that are expanding its potential across gene therapies and retinal therapeutics
- Evaluate the strengths, limitations, and development considerations of emerging suprachoroidal delivery technologies to accelerate program success and avoid common pitfalls
- Gain practical insights from preclinical and clinical experience on optimising dose, volume, delivery technique, and target engagement to improve outcomes and reduce development risk
2:45 pm Leveraging Hydrogel Delivery Technologies to Improve Cell Therapy Engraftment & Retinal Regeneration
- Examine how injectable hydrogel scaffolds can protect therapeutic cells during administration, improve retention at the target site, and enhance long-term functional integration
- Understand the practical considerations involved in selecting surgical delivery devices, designing translational studies, and generating the evidence needed to support regulatory approval
- Explore how hydrogel platforms are being adapted for cell therapies, gene therapies, and other advanced modalities to improve efficacy, safety, and clinical adoption
3:15 pm Engineering Precision Delivery: Integrating Device Engineering, Preclinical Modeling, & Molecule Development for Efficient Therapeutic Selection
- Understand how developing species-specific delivery to reliably target the tissue of interest improves therapeutic down selection
- See how our team has modified our clinical devices for preclinical anatomy, how we evaluate the designs, and what cross-functional subject matter experts should be included
- Learn how subretinal delivery of AAV gene therapy via alternative routes effects ocular inflammatory profiles
3:45 pm Afternoon Break & Poster Session
Join an engaging poster session designed to encourage meaningful conversations, collaboration, and knowledge exchange in a relaxed setting. Explore innovative presentations in ophthalmic drug delivery and showcase your research and developments. Connect with experts, discover new insights, and share your work with the community.
Navigating Regulatory Pathways & Clinical Development to Accelerate Ophthalmic Product Approval
4:45 pm Roundtable Discussion: Accelerating Regulatory Approval by Applying Lessons from Successful & Challenged Ophthalmic Programs
- Learn directly from developers who have navigated approvals, regulatory delays, and setbacks to identify the strategies that improve submission success and reduce risk
- Understand common reasons for complete response letters and how to proactively address these issues in your development plan
- Discuss emerging regulatory considerations for novel modalities including gene therapies, cell therapies, and extended-release implants where precedents are still being established
5:15 pm Building More Predictive Preclinical Strategies for Successful Clinical Translation
- Discuss the importance of preclinical model selection and data quality in improving translation from preclinical studies to human trials
- Explore how endpoint selection should be scientifically driven by the chosen preclinical model and aligned with clinically relevant features of the human disease
- Examine how preclinical readouts can be evaluated for their relevance and predictive value in human trials, helping identify models with greater translational potential